INa, Sodium current

  • 文章类型: Journal Article
    糖原合成酶激酶3(GSK-3)抑制已成为几种疾病的潜在治疗靶点。包括癌症.然而,GSK-3调节人体心脏电生理的作用仍不明确。我们证明了SB216763,一种GSK-3抑制剂,可以急剧降低人体心脏切片的传导速度。结合计算模型和实验方法提供了对GSK-3抑制介导的变化的机械洞察,揭示钠通道电导和组织电导率降低可能是观察到的表型的基础。我们的研究表明,人心肌中的GSK-3抑制作用会改变电生理,并可能易患心律失常底物;因此,可以考虑监测不良致心律失常事件.
    Glycogen synthase kinase 3 (GSK-3) inhibition has emerged as a potential therapeutic target for several diseases, including cancer. However, the role for GSK-3 regulation of human cardiac electrophysiology remains ill-defined. We demonstrate that SB216763, a GSK-3 inhibitor, can acutely reduce conduction velocity in human cardiac slices. Combined computational modeling and experimental approaches provided mechanistic insight into GSK-3 inhibition-mediated changes, revealing that decreased sodium-channel conductance and tissue conductivity may underlie the observed phenotypes. Our study demonstrates that GSK-3 inhibition in human myocardium alters electrophysiology and may predispose to an arrhythmogenic substrate; therefore, monitoring for adverse arrhythmogenic events could be considered.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在包括Brugada综合征在内的各种心律失常患者中鉴定出SCN5A基因的遗传变异。尽管过去几十年在研究心律失常相关SCN5A突变的分子机制方面取得了重大进展,对遗传学之间关系的理解,电生理后果和临床表型缺乏。我们在Brugada综合征(BrS)男性患者的SCN5A编码的钠通道Nav1.5中发现了一种新的遗传变异体Y739D。该研究的目的是表征Nav1.5-Y739D的生物物理特性,并提供在患者中观察到的表型的可能解释。WT和Y739D通道在HEK-293T细胞中异源表达,并记录全细胞钠电流。替代Y739D在-20mV时将钠电流密度降低了47±2%,正移位的电压依赖性激活,加速了快速和缓慢的失活,并从缓慢失活中减速恢复。Y739D功能丧失表型可能导致BrS表现。在hNav1.5同源性模型中,基于大鼠Nav1.5通道的低温EM结构,细胞外环IIS1-S2中的Y739与K1381和E1435形成H-键,并且π-阳离子与K1397接触(全部在环IIIS5-P1中)。相比之下,Y739D接受K1397和Y1434的H债券。Y739和Y739D与环IIIS5-P1的实质上不同的接触将不同地将变构信号从VSD-II传输到螺旋IIIS5的N端的快速失活栅极和螺旋IIIP1的C端的慢速失活栅极。这可能是Y739D通道功能障碍的原子机制的基础。
    Genetic variants in SCN5A gene were identified in patients with various arrhythmogenic conditions including Brugada syndrome. Despite significant progress of last decades in studying the molecular mechanism of arrhythmia-associated SCN5A mutations, the understanding of relationship between genetics, electrophysiological consequences and clinical phenotype is lacking. We have found a novel genetic variant Y739D in the SCN5A-encoded sodium channel Nav1.5 of a male patient with Brugada syndrome (BrS). The objective of the study was to characterize the biophysical properties of Nav1.5-Y739D and provide possible explanation of the phenotype observed in the patient. The WT and Y739D channels were heterologously expressed in the HEK-293T cells and the whole-cell sodium currents were recorded. Substitution Y739D reduced the sodium current density by 47 ± 2% at -20 mV, positively shifted voltage-dependent activation, accelerated both fast and slow inactivation, and decelerated recovery from the slow inactivation. The Y739D loss-of-function phenotype likely causes the BrS manifestation. In the hNav1.5 homology models, which are based on the cryo-EM structure of rat Nav1.5 channel, Y739 in the extracellular loop IIS1-S2 forms H-bonds with K1381 and E1435 and pi-cation contacts with K1397 (all in loop IIIS5-P1). In contrast, Y739D accepts H-bonds from K1397 and Y1434. Substantially different contacts of Y739 and Y739D with loop IIIS5-P1 would differently transmit allosteric signals from VSD-II to the fast-inactivation gate at the N-end of helix IIIS5 and slow-inactivation gate at the C-end of helix IIIP1. This may underlie the atomic mechanism of the Y739D channel dysfunction.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号